Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cue Biopharma Inc (NQ: CUE )

2.130 +0.250 (+13.30%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 3, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 663,094
Open 1.900
Bid (Size) 2.020 (1)
Ask (Size) 2.130 (45)
Prev. Close 1.880
Today's Range 1.870 - 2.190
52wk Range 1.303 - 5.120
Shares Outstanding 44,959,548
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Cue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
From Cue Biopharma, Inc.
Via GlobeNewswire

Performance

YTD
-23.38%
-23.38%
1 Month
+19.66%
+19.66%
3 Month
-10.50%
-10.50%
6 Month
-16.47%
-16.47%
1 Year
-56.44%
-56.44%

More News

Read More
Forecasting The Future: 4 Analyst Projections For Cue Biopharma
Via Benzinga
Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business Highlights
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma Inc. (NASDAQ: CUE) Leading the Way in Wednesday Trading Based on Percentage Gain
Via Investor Brand Network
Where Cue Biopharma Stands With Analysts
Via Benzinga
CUE Stock Earnings: Cue Biopharma Misses EPS, Beats Revenue for Q4 2023
Via InvestorPlace
Cue Biopharma to Host Business Update Call and Webcast
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma’s Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers Symposium
From Cue Biopharma, Inc.
Via GlobeNewswire
Why Clover Health Investments Shares Are Trading Higher By 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Cue Biopharma to Present Corporate Update at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
From Cue Biopharma, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
CUE Stock Earnings: Cue Biopharma Beats EPS, Beats Revenue for Q3 2023
Via InvestorPlace
Cue Biopharma to Present at the JMP Securities Hematology and Oncology Summit
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma Reports Third Quarter 2023 Financial Results and Recent Business Highlights
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma to Present at Three Upcoming Investor Healthcare Conferences in November
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma Presents New Positive Data from Phase 1 Trials of CUE-101 in Head and Neck Cancer and CUE-102 in Wilms’ Tumor 1 Positive Cancers at SITC 2023
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma to Host Business Update Call and Webcast
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma Announces Completion of Patient Enrollment in Phase 1b Study of CUE-101 in Combination with KEYTRUDA®
From Cue Biopharma, Inc.
Via GlobeNewswire
The Truth About IPO Investing
Via Talk Markets
Topics Initial Public Offering
Exposures Securities Market
Cue Biopharma And 2 Other Stocks Under $3 Insiders Are Buying
Via Benzinga
Topics Stocks
Exposures US Equities
Cue Biopharma Reports Second Quarter 2023 Financial Results and Recent Business Highlights
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma to Host Business Update Call and Webcast
From Cue Biopharma, Inc.
Via GlobeNewswire
3 Biotech Stocks to Buy as Companies Ink Major Deals
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.